You are here

Drug eluting Brachytherapy Implants for Chemo radiation Therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA224646-01
Agency Tracking Number: R41CA224646
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-25
Award End Date (Contract End Date): 2019-09-24
Small Business Information
41 ESTY FARM RD, Newton, MA, 02459-3605
DUNS: 079591740
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 (617) 755-3838
Business Contact
Phone: (617) 755-3838
Research Institution
 360 HUNTINGTON AVE, 177-500
BOSTON, MA, 02115-5005
 Nonprofit college or university
Prostate cancer PCa is the second leading cause of cancer death in American men with deaths and new cases estimated in the US in Radiation therapy is one of the standard therapies for high and intermediate risk patients and is a non surgical therapy option for low risk patients A combined chemo radiation therapy CRT approach has been shown in several trials to improve survival in multiple cancers compared with monotherapies However systemic chemotherapy accompanying CRT typically come at the price of increased toxicity and thus require synchronization of the two modalities to achieve maximum benefit Here an immediate need exists to deliver the drug specifically at tumor site in locally recurrent patients while avoiding toxicities associated with systemic delivery and resulting in preferential radiosensitization of the prostate compared to the normal structures Northeastern University and Theranano LLC in collaboration with clinicians at Brigham and Womens Hospital and Dana Farber Cancer Institute have developed an innovative combinatorial treatment strategy of Local Chemo Radiation Therapy LCRT using a modified brachytherapy spacer platform in the form of a INCeRT ImplaNts for ChemoRadiation Therapy spacer loaded with Docetaxel DTX to locally radiosensitize the prostate enabling a synergistic cure with the use of lower radiation doses thereby leading to less rectal radiation toxicity and minimal chemotherapeutic systemic side effects These new INCeRT spacers are physically similar to the inert spacers routinely used in prostate brachytherapy but now loaded with formulations of DTX which can be tuned to release the drug payload from a week to several months The technology has been exclusively licensed to TheraNano LLC for commercialization and translation to the clinic The phase project goals will be achieved through the following specific aims Specific Aim Development scale up and quality control of docetaxel loaded INCeRT brachytherapy spacers Develop INCeRT brachytherapy spacers loaded with DTX with analysis of quality control reproducibility drug loading and drug release using optimized SOPs Earlier work at Northeastern University has produced INCeRT spacers in batches of andlt Here we plan to scale up the process to routinely manufacture DTX INCeRT spacers in batches of several s in GLP conditions The study design will include setting up a pilot plant for fabrication characterization of INCeRT spacers loaded with docetaxel and quality control assessment in terms of reproducibility size drug loading and release kinetics under GLP conditions Specific Aim In vivo therapeutic efficacy of combined Chemo Radiation treatment and toxicity assessment in Prostate cancer models We will evaluate the therapeutic efficacy of INCeRT spacers combined with Brachytherapy EBRT by locally implanting the spacers at the tumor site in PCa animal models We will also assess gross immunotoxicity associated with the combined treatment PROJECTNARRATIVE TITLE Drug eluting Brachytherapy Implants for Chemo radiation Therapy This STTR phase project seeks to demonstrate the feasibility of drug eluting brachytherapy implants for Local Chemo Radiation Therapy LCRT as a new modality of prostate cancer treatment LCRT combines radiation therapy with chemotherapy delivered locally to the prostate utilizing drug releasing spacers similar to those currently used in brachytherapy to boost the overall treatment efficiency while greatly reducing toxic side effects The treatment has the potential to improve the lives of all of the thousands of men with localized prostate cancer who are treated each year with radiation therapy

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government